The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Helfer, Markus ^a   Koppensteiner, Herwig ^a   Schneider, Martha ^a   Rebensburg, Stephanie ^a   Forcisi, Sara ^a   Müller, Constanze ^a   Schmitt Kopplin, Philippe ^a   Schindler, Michael ^a   Brack Werner, Ruth ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; GRIFFITHSIN; HUMAN IMMUNODEFICIENCY VIRUS 1 ATTACHMENT INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PELARGONIUM SIDOIDES EXTRACT; PLERIXAFOR; POLYPHENOL DERIVATIVE; UMCKALOABO; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ISOLATION; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLANT ROOT; PROPHYLAXIS; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; PELARGONIUM; PLANT EXTRACTS; PLANT ROOTS; PLANTS, MEDICINAL; POLYPHENOLS; VIRUS ATTACHMENT;

EID: 84900345359     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087487     Document Type: Article

References (48)

1. AIDSinfo USDoHaHSH (2012) HIV and Its Treatment - FDA-Approved Anti-HIV Medications.
2. Tang MW, Shafer RW (2012) HIV-1 Antiretroviral resistance: Scientific principles and clinical applications. Drugs 72: e1-e25.
3. Stadeli KM, Richman DD (2012) Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antiviral therapy.
4. Marcus KA, Sorbello A, Truffa M, Williams J, Raine JM, et al. (2012) Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV. Current Opinion in HIV and AIDS 7: 292-298.
5. Vella S, Schwartländer B, Sow SP, Eholie SP, Murphy RL (2012) The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26: 1231-1241.
6. Hawkins T (2010) Understanding and managing the adverse effects of antiretroviral therapy. Antiviral research 85: 201-209.
7. Cordell GA, Colvard MD (2012) Natural products and traditional medicine: turning on a paradigm. Journal of natural products 75: 514-525.
8. Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, et al. (2008) Antiviral potentials of medicinal plants. Virus research 131: 111-120. (Pubitemid 351192951)
9. Singh IP, Bodiwala HS (2010) Recent advances in anti-HIV natural products. Natural product reports 27: 1781-1800.
10. Cos P, Maes L, Vlietinck A, Pieters L (2008) Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection-an update (1998-2007). Planta Med 74: 1323-1337.
11. Gertsch J (2011) Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Medica-Natural Products and Medicinal-Plant Research 77: 1086.
12. Brendler T, Van Wyk B-E (2008) A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). Journal of ethnopharmacology 119: 420-433.
13. Kolodziej H (2007) Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo ® Phytomedicine 14: 9-17.
14. Michaelis M, Doerr HW, Cinatl J (2011) Investigation of the influence of EPs H 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine 18: 384-386.
15. Theisen LL, Muller CP (2012) EPs H 7630 (UmckaloaboH), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral research.
16. Schnitzler P, Schneider S, Stintzing F, Carle R, Reichling J (2008) Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus. Phytomedicine: international journal of phytotherapy and phytopharmacology 15: 1108.
17. Kremb S, Helfer M, Heller W, Hoffmann D, Wolff H, et al. (2010) EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrobial agents and chemotherapy 54: 5257-5268.
18. ELI. Virology 185: 661-672.
19. Freed EO, Englund G, Martin MA (1995) Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. Journal of virology 69: 3949-3954.
20. Koppensteiner H, Banning C, Schneider C, Hohenberg H, Schindler M (2012) Macrophage internal HIV-1 is protected from neutralizing antibodies. Journal of virology 86: 2826-2836.
21. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, et al. (2004) Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. Journal of virology 78: 6915-6926. (Pubitemid 38781530)
22. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, et al. (2013) Phenotypic properties of transmitted founder HIV-1. Proceedings of the National Academy of Sciences 110: 6626-6633.
23. Jones J, Whitford W, Wagner F, Kutsch O (2007) Optimization of HIV-1 infectivity assays. BioTechniques 43: 589.
24. Fuss IJ, Kanof ME, Smith PD, Zola H (2009) Isolation of whole mononuclear cells from peripheral blood and cord blood. Current Protocols in Immunology7.11-7.1. 8.
25. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, et al. (1994) Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrobial agents and chemotherapy 38: 668-674. (Pubitemid 24113999)
26. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial agents and chemotherapy 44: 1667-1673. (Pubitemid 30340812)
27. Mori T, O'Keefe BR, Sowder II RC, Bringans S, Gardella R, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. Journal of Biological Chemistry 280: 9345-9353.
28. Daelemans D, Pauwels R, De Clercq E, Pannecouque C (2011) A time-of-drug addition approach to target identification of antiviral compounds. Nature Protocols 6: 925-933.
29. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature medicine 4: 1302-1307. (Pubitemid 28512112)
30. De Clercq E (2009) The history of antiretrovirals: key discoveries over the past 25 years. Reviews in medical virology 19: 287-299.
31. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes 37: 1253-1262. (Pubitemid 39281506)
32. Sluis-Cremer N, Tachedjian G (2008) Mechanisms of inhibition of HIV replication by nonnucleoside reverse transcriptase inhibitors. Virus research 134: 147.
33. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, et al. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. Journal of virology 85: 9039-9050.
34. Forcisi S, Moritz F, Kanawati B, Tziotis D, Lehmann R, et al. (2013) Liquid chromatography-mass spectrometry in metabolomics research: Mass analyzers in ultra high pressure liquid chromatography coupling. Journal of Chromatography A 1292: 51-65.
35. Overy DP, Enot DP, Tailliart K, Jenkins H, Parker D, et al. (2008) Explanatory signal interpretation and metabolite identification strategies for nominal mass FIE-MS metabolite fingerprints. Nature Protocols 3: 471-485. (Pubitemid 351372234)
36. Magalhães PJ, Vieira JS, Gonçalves LM, Pacheco JG, Guido LF, et al. (2010) Isolation of phenolic compounds from hop extracts using polyvinylpolypyrrolidone: characterization by high-performance liquid chromatography-diode array detection-electrospray tandem mass spectrometry. Journal of chromatography 1217: 3258-3268.
37. François K, Balzarini J (2010) Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Medicinal Research Reviews 32: 349-387.
38. Huskens D, Schols D (2012) Algal lectins as potential HIV microbicide candidates. Marine drugs 10: 1476-1497.
39. Hertje M, Zhou M, Dietrich U (2010) Inhibition of HIV-1 Entry: Multiple Keys to Close the Door. ChemMedChem 5: 1825-1835.
40. Gibson R, Arts E (2012) Past, Present, and Future of Entry Inhibitors as HIV Microbicides. Current HIV research 10: 19.
41. Krepstakies M, Lucifora J, Nagel C-H, Zeisel MB, Holstermann B, et al. (2012) A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. Journal of Infectious Diseases 205: 1654-1664.
42. Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T (2002) Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral research 53: 19-34. (Pubitemid 33001552)
43. Hamza A, Zhan C-G (2006) How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. The Journal of Physical Chemistry B 110: 2910-2917. (Pubitemid 43342887)
44. Yang J, Li L, Tan S, Jin H, Qiu J, et al. (2011) A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: Potential applications for preventing HIV-1 infection. Fitoterapia.
45. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, et al. (2000) Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. Journal of virology 74: 1948-1960. (Pubitemid 30434054)
46. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrobial agents and chemotherapy 49: 4721-4732. (Pubitemid 41552605)
47. Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, et al. (2011) Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. Plos one 6: e22635.
48. Timmer A, Günther J, Rücker G, Motschall E, Antes G, et al. (2008) Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev 3.